Canaccord Genuity Group Lowers Definitive Healthcare (NASDAQ:DH) Price Target to $3.00

Definitive Healthcare (NASDAQ:DH) had its price objective reduced by Canaccord Genuity Group from $4.00 to $3.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “hold” rating on the stock. Canaccord Genuity Group’s price objective indicates a potential upside of 134.38% from the stock’s previous close.

Several other brokerages also recently weighed in on DH. Barclays decreased their target price on Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating for the company in a research report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Definitive Healthcare in a report on Wednesday, January 21st. William Blair raised shares of Definitive Healthcare to a “strong-buy” rating in a research report on Thursday, November 6th. Morgan Stanley reiterated an “underperform” rating and set a $3.50 price objective on shares of Definitive Healthcare in a research note on Thursday, December 18th. Finally, Stephens decreased their target price on shares of Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.52.

Definitive Healthcare Stock Down 8.6%

Shares of Definitive Healthcare stock opened at $1.28 on Friday. Definitive Healthcare has a twelve month low of $1.14 and a twelve month high of $4.70. The stock has a market cap of $180.94 million, a price-to-earnings ratio of -1.02 and a beta of 1.59. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.41. The company has a fifty day moving average price of $2.18 and a 200 day moving average price of $2.87.

Hedge Funds Weigh In On Definitive Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. increased its stake in shares of Definitive Healthcare by 564.2% in the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after buying an additional 7,404,363 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Definitive Healthcare by 1.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,073,197 shares of the company’s stock worth $8,417,000 after acquiring an additional 33,612 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Definitive Healthcare by 11.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,216,007 shares of the company’s stock worth $4,937,000 after purchasing an additional 127,055 shares during the last quarter. Bank of America Corp DE increased its position in shares of Definitive Healthcare by 23.7% in the 2nd quarter. Bank of America Corp DE now owns 769,397 shares of the company’s stock worth $3,001,000 after purchasing an additional 147,599 shares during the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Definitive Healthcare by 0.4% in the 2nd quarter. New York State Common Retirement Fund now owns 766,433 shares of the company’s stock valued at $2,989,000 after purchasing an additional 3,066 shares in the last quarter. 98.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Definitive Healthcare

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Q4 revenue came in roughly in-line to slightly above estimates (reported ~$61.5M vs. some analyst estimates around $59–61M), showing top-line stability versus a year ago. Read More.
• Positive Sentiment: Cash and cash equivalents increased year-over-year (reported ~$163.6M), which supports near-term liquidity. Read More.
• Neutral Sentiment: Reported GAAP EPS results were reported as meeting some consensus figures (sources show EPS in-line with a $0.06 consensus), so headline EPS didn’t surprise to the upside. Read More.
• Neutral Sentiment: Brokerage consensus has settled around a “Hold” average recommendation, reflecting mixed views across analysts. Read More.
• Negative Sentiment: The company cut guidance: Q1 FY2026 EPS guidance (~$0.03) and revenue guidance ($54M–$56M) both sit below consensus, and full‑year 2026 guidance ($0.14–$0.17 EPS; $220M–$226M revenue) also trails Street expectations — the primary driver of today’s downside. Read More.
• Negative Sentiment: Analysts lowered price targets and kept cautious ratings (Canaccord cut its target from $4.00 to $3.00 with a Hold; Stephens trimmed its target to $2.00 with Equal Weight), amplifying selling pressure. Read More.
• Negative Sentiment: Underlying profitability metrics showed deterioration in some reports (wider operating loss and larger net loss year-over-year), and multiple institutional holders trimmed positions in the latest quarter, suggesting reduced confidence from larger investors. Read More.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.